Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation
Translation Control Discovery Platform
A new strategy against hard and undruggable targets
Specifically decrease or increase the production of target proteins
Translation Control Lab
Anima’s Translation Control Lab (TCL) is purpose-built for the discovery of translation modulators by integrating our proprietary technologies in biology, bioinformatics, big data image analysis and cloud software architecture
• Analysis Assessment
• Bio Data Analysis
Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (monitoring mutant Huntingtin translation pausing).
$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
For partnering inquiries, please contact email@example.com.
17 Scientific Collaborations
Eur J Cell Biol (2018) ; 97 : 168-179.
Integr Biol (2016); 8 :645-53
J Cell Biol. 2016; 23;213(4):451-62.
Nucleic Acid Res. (2017); 45 :926-937
News & Events
2019 BIO Asia
When: Mar. 5th, 2019 - Mar. 6th, 2019
Where: Tokyo, Japan
Anima Biotech has been invited to present about its business and partnering strategies at the 2019 BIO Asia International Conference.
The Annual BIO Asia International Conference is an exclusive, customized partnering forum that brings together U.S. and European drug development companies with Asian biotech and pharmaceutical companies interested in research collaborations and licensing agreements.
12th Annual European Life Sciences CEO Forum
When: Feb. 25th, 2019 - Feb. 26th, 2019
Where: Zurich, Switzerland
Anima Biotech has been invited to both present and participate on a panel during the 12th Annual European Life Sciences CEO Forum.
Back for its 12th Annual edition, the global biopharma industry forum addresses through its conference the main challenges for 2019 in investment, partnering and alliance management. Key players contribute their insights in panels, which cover the macro picture as well as innovation in the different therapeutic sectors.
BIO CEO & Investor Conference
When: Feb. 11th, 2019 - Feb. 12th, 2019
Where: New York, USA
Anima Biotech has participated and presented at the 2019 CEO & Investor Conference.
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities.
Over the years, as Anima was still developing its technology platform, I attended many conferences in which I was selling our vision to pharma. I always received these responses; "this is so novel," "this platform has huge potential," but also heard "this is very early," "what results do you...
January 31st, 2019